SCHEMBL6907539

SCHEMBL6907539

Cc1ccc2c3c(ccc2n1)OCC(CN1CCCCC1)O3

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 15/20 0.69
CYP3A4 P08684 1/20 0.61
CYP2C8 P10632 1/20 0.61
DRD2 P14416 1/20 0.61
DRD4 P21917 1/20 0.61
CYP2C19 P33261 1/20 0.61
DRD3 P35462 1/20 0.61
SLC6A4 P31645 1/20 0.57
ADRA2A P08913 1/20 0.50
ADRA2B P18089 1/20 0.50
ADRA2C P18825 1/20 0.50
ADRA1D P25100 1/20 0.50
ADRA1A P35348 1/20 0.50
ADRA1B P35368 1/20 0.50
SCN1A P35498 1/20 0.50
SCN2A Q99250 1/20 0.50
SCN3A Q9NY46 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5912597 0.89 HTR1A (0.66) HTR1ACYP3A4CYP2C8DRD2DRD4
SCHEMBL5912602 0.89 HTR1A (0.66) HTR1ACYP3A4CYP2C8DRD2DRD4
SCHEMBL4187208 0.88 HTR1A (0.65) HTR1ACYP3A4CYP2C8DRD2DRD4
SCHEMBL5912925 0.84 HTR1A (0.75) HTR1ACYP3A4CYP2C8DRD2DRD4
SCHEMBL5912688 0.84 HTR1A (0.67) HTR1ACYP3A4CYP2C8DRD2DRD4
SCHEMBL5912846 0.83 HTR1A (0.83) HTR1ACYP3A4CYP2C8DRD2DRD4
SCHEMBL5912850 0.83 HTR1A (0.69) HTR1ACYP3A4CYP2C8DRD2DRD4
SCHEMBL5912832 0.82 HTR1A (1.00) HTR1ACYP3A4CYP2C8DRD2DRD4
SCHEMBL5912613 0.82 HTR1A (0.65) HTR1ACYP3A4CYP2C8DRD2DRD4
SCHEMBL13927903 0.82 HTR1A (0.56) HTR1ACYP3A4CYP2C8DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6821981-B2 FOR THERAPY OF DISORDERS, SUCH AS ANXIETY, AGGRESSION AND STRESS, AND FOR THE CONTROL OF VARIOUS PHYSIOLOGICAL PHENOMENA, SUCH AS APPETITE, THERMOREGULATION, SLEEP AND SEXUAL BEHAVIOR WYETH 2004-11-23 US claimed
US-20020193366-A1 Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists WYETH 2002-12-19 US claimed
WO-2002088132-A1 AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE AS 5-HT1AANTAGONISTS WYETH (US) 2002-11-07 WO claimed
US-6821981-B2 FOR THERAPY OF DISORDERS, SUCH AS ANXIETY, AGGRESSION AND STRESS, AND FOR THE CONTROL OF VARIOUS PHYSIOLOGICAL PHENOMENA, SUCH AS APPETITE, THERMOREGULATION, SLEEP AND SEXUAL BEHAVIOR WYETH 2004-11-23 US disclosed
US-20020193366-A1 Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists WYETH 2002-12-19 US disclosed
WO-2002088132-A1 AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE AS 5-HT1AANTAGONISTS WYETH (US) 2002-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193366-A1 Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists HTR2C, HTR1A, HTR3B HTR1A 2/4885CYP3A4 259/4885CYP2C8 809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.